» Articles » PMID: 18239126

Cancer Proliferation Gene Discovery Through Functional Genomics

Abstract

Retroviral short hairpin RNA (shRNA)-mediated genetic screens in mammalian cells are powerful tools for discovering loss-of-function phenotypes. We describe a highly parallel multiplex methodology for screening large pools of shRNAs using half-hairpin barcodes for microarray deconvolution. We carried out dropout screens for shRNAs that affect cell proliferation and viability in cancer cells and normal cells. We identified many shRNAs to be antiproliferative that target core cellular processes, such as the cell cycle and protein translation, in all cells examined. Moreover, we identified genes that are selectively required for proliferation and survival in different cell lines. Our platform enables rapid and cost-effective genome-wide screens to identify cancer proliferation and survival genes for target discovery. Such efforts are complementary to the Cancer Genome Atlas and provide an alternative functional view of cancer cells.

Citing Articles

3D bioprinting for the construction of drug testing models-development strategies and regulatory concerns.

Mallya D, Gadre M, Varadharajan S, Vasanthan K Front Bioeng Biotechnol. 2025; 13:1457872.

PMID: 40028291 PMC: 11868281. DOI: 10.3389/fbioe.2025.1457872.


dysfunction in VEXAS and cancer.

Sakuma M, Haferlach T, Walter W Oncotarget. 2024; 15:644-658.

PMID: 39347709 PMC: 11441413. DOI: 10.18632/oncotarget.28646.


RTF2 controls replication repriming and ribonucleotide excision at the replisome.

Conti B, Ruiz P, Broton C, Blobel N, Kottemann M, Sridhar S Nat Commun. 2024; 15(1):1943.

PMID: 38431617 PMC: 10908796. DOI: 10.1038/s41467-024-45947-z.


Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science.

Stuart D, Guzman-Perez A, Brooijmans N, Jackson E, Kryukov G, Friedman A Cancer Discov. 2023; 13(10):2131-2149.

PMID: 37712571 PMC: 10551669. DOI: 10.1158/2159-8290.CD-23-0280.


Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer.

Kondratyev M, Pesic A, Ketela T, Stickle N, Beswick C, Shalev Z Commun Biol. 2023; 6(1):538.

PMID: 37202533 PMC: 10195806. DOI: 10.1038/s42003-023-04828-9.


References
1.
Berns K, Hijmans E, Mullenders J, Brummelkamp T, Velds A, Heimerikx M . A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature. 2004; 428(6981):431-7. DOI: 10.1038/nature02371. View

2.
Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View

3.
Westbrook T, Martin E, Schlabach M, Leng Y, Liang A, Feng B . A genetic screen for candidate tumor suppressors identifies REST. Cell. 2005; 121(6):837-48. DOI: 10.1016/j.cell.2005.03.033. View

4.
Kolfschoten I, van Leeuwen B, Berns K, Mullenders J, Beijersbergen R, Bernards R . A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell. 2005; 121(6):849-58. DOI: 10.1016/j.cell.2005.04.017. View

5.
Dickins R, Hemann M, Zilfou J, Simpson D, Ibarra I, Hannon G . Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet. 2005; 37(11):1289-95. DOI: 10.1038/ng1651. View